# US 2019/0375742 A1 · Benzothiazole derivatives as dyrk1 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375742 A1
- Document ID: US20190375742A1
- Status: Published application
- Kind: A1
- Application number: 16/341,630
- Filed: 2017-10-12
- Published: 2019-12-12
- Earliest claimed: 2016-10-12
- Assignees: Pharmasum Therapeutics AS
- Applicants: Pharmasum Therapeutics AS
- Inventors: John Sigurd Svendsen; Wenche Stensen; Roderick Alan Porter
- Web page: https://patentgrep.com/patent/US20190375742A1

## CPC

- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- A61P 35/00: Antineoplastic agents
- C07D 417/14: containing three or more hetero rings
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors, and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic disorders such as Metabolic Syndrome or diabetes mellitus, and cancer.

## Claims

### Claim 1

A compound of Formula (I),
wherein
R1 is selected from the group consisting of fluorine, an OR2 group, a CONHR3 group, CH2C(O)NHR3 and —C≡CR2;
R2 is hydrogen or a C1-3 alkyl group;
R3 is hydrogen or a C1-3 alkyl group; and
R1a is H;
or
R1 and R1a together form a 5- or 6-membered unsubstituted ring, optionally containing a heteroatom selected from N, O or S;
X is a five- or six-membered aromatic heterocyclic group, containing one or two nitrogen atoms in the ring, and which is substituted with a first substituent R4, and optionally, a second substituent R5, wherein R4 and R5, if present, are attached to a carbon atom in the heterocyclic group;
R4 and R5, which may be the same or different, are each a group represented by Formula (II),
V—W—Y—Z (II)
wherein
the covalent bonds V—W, W—Y, and Y—Z are single, double or triple bonds;
V represents C, N or F, if V is C, the C may be substituted by O, OH, F, F2 or F3, and if V is N, the N may be substituted by a C1-3 alkyl group;
W represents C, N, O, S, or is absent, if W is C, the C may be substituted by O, OH, CH3, F, F2 or F3, if W is N, the N may be substituted by a C1-3 alkyl group and if W is S, the S is substituted by O or (O)2, preferably (O)2;
or
W represents a 5- or 6-membered carbocyclic group, or a 5- or 6-membered heterocyclic group having at least one ring N atom and optionally also a further heteroatom in the ring selected from N, O and S, wherein W may optionally be substituted by one or two halogen atoms;
Y represents C, N, O, S or is absent, if Y is C, the C may be substituted by O, OH, CH3, F, F2 or F3;
or
Y represents a 5- or 6-membered carbocyclic group, or a 5- or 6-membered heterocyclic group containing 1 or 2 nitrogen atoms in the ring, and optionally substituted by one or two groups, which may be the same or different, selected from OH, NH2, NH(CO)CH3, CH2NH2, CH2NHC1-3 alkyl and CH2N(C1-3 alkyl)2;
Z represents C, N, O or is absent, if Z is C, the C may be substituted by O, OH, NH2, or CH3, if Z is N, the N may be substituted by C(O)C1-4alkyl, S(O)2C1-4alkyl or CHR4aCOOH, wherein R4a is selected from H, CH3, CH(CH3)2, CH2OH or CH(OH)CH3, if Z is O, the O may be substituted by C1-4alkyl;
wherein if W, Y and Z are absent from R4 and R5 is also absent, V is not unsubstituted N or C;
wherein R5, if present, comprises six or fewer non-hydrogen atoms;
or a pharmaceutically acceptable salt, hydrate, solvate or tautomer thereof,
but excluding the following compounds:

### Claim 2 (depends on 1)

A compound as claimed in claim 1 of Formula (III)
or Formula (IV)
or Formula (V)
wherein X is as defined in claim 1.

### Claim 3 (depends on 1)

A compound as claimed in claim 1 wherein X contains one nitrogen atom in the ring.

### Claim 4 (depends on 1)

A compound as claimed in claim 1 wherein X is a six-membered cyclic group.

### Claim 5 (depends on 4)

A compound as claimed in claim 4 wherein the six-membered cyclic group has at least one nitrogen atom present in the meta-position.

### Claim 6 (depends on 1)

A compound as claimed in claim 1 wherein R4 is selected from the substituents depicted in Table 1.

### Claim 7 (depends on 1)

A compound as claimed in claim 1 wherein R5 is absent.

### Claim 8 (depends on 1)

A compound as claimed in claim 1 wherein R4 has no more than 14 non-hydrogen atoms.

### Claim 9 (depends on 1)

A compound as claimed in claim 1, wherein if X is a six-membered group having a nitrogen atom present in the meta-position, then neither the R4 substituent nor the R5 substituent is present at the para-position.

### Claim 10 (depends on 1)

A compound as claimed in claim 1 wherein the R4 substituent and if present the R5 substituent, are present at the ortho- and/or meta-position, preferably the meta-position.

### Claim 11 (depends on 1)

A compound as claimed in claim 1 wherein V represents unsubstituted C or N.

### Claim 12 (depends on 1)

A compound as claimed in claim 1 wherein W represents unsubstituted C, unsubstituted N, C substituted by O, S substituted by (O)2, a 6-membered carbocyclic group, or a 6-membered heterocyclic group having one ring N atom.

### Claim 13 (depends on 1)

A compound as claimed in claim 1 wherein Y represents unsubstituted N or C or C substituted by O or CH3.

### Claim 14 (depends on 1)

A composition comprising a compound as claimed in claim 1 and a suitable carrier, diluent or excipient.

### Claim at position 15

15-16. (canceled)

### Claim 17 (depends on 1)

A method of treating or preventing a neurodegenerative disorder, a metabolic disorder, or cancer, in a subject comprising administering to said subject a therapeutically effective amount of a compound of formula (I) as defined in claim 1.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The method of claim 17 wherein the method is a method of treating or preventing a neurodegenerative disorder, and wherein the neurodegenative disorder is Alzheimer's disease or Parkinson's disease.

### Claim 20 (depends on 19)

The method of claim 19 wherein the subject has Down Syndrome.

### Claim 21

(canceled)

### Claim 22 (depends on 17)

The method of claim 17, wherein the method is a method of treating or preventing a metabolic disorder, and wherein the metabolic disorder is Metabolic Syndrome or diabetes mellitus.

### Claim at position 22

23-24. (canceled)

### Claim 25 (depends on 17)

The method of claim 17, wherein the method is a method of treating or preventing cancer.

### Claim 26

(canceled)
